| Strength: | |
|---|---|
| Quantity: | |
Brief Introduction:
Launched in 2023.
Pegneugen is a national Class 1 new drug, therapeutic biological product. It is modified with 40kD Y-shape branched polyethylene glycol (PEG) and granted with a new International Nonproprietary Name (INN), i.e. Telpegfilgrastim, from WHO.
Indications:
Telpegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Telpegfilgrastim is not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. See package insert for details.
Brief Introduction:
Launched in 2023.
Pegneugen is a national Class 1 new drug, therapeutic biological product. It is modified with 40kD Y-shape branched polyethylene glycol (PEG) and granted with a new International Nonproprietary Name (INN), i.e. Telpegfilgrastim, from WHO.
Indications:
Telpegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Telpegfilgrastim is not indicated for mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. See package insert for details.
